DGAP-News: Alacris Theranostics ModCellTM system will use the SAP HANA(R) platform to speed up in silico modeling of drug responses during patient treatments as well as for drug development and approval.

DGAP-News: Alacris Theranostics GmbH / Key word(s): Alliance
Alacris Theranostics ModCellTM system will use the SAP HANA(R)
platform to speed up in silico modeling of drug responses during
patient treatments as well as for drug development and approval.

01.04.2014 / 09:30

---------------------------------------------------------------------

Press Release 

______________________________________________________________

Alacris Theranostics ModCellTM system will use the SAP HANA(R) platform to
speed up in silico modeling of drug responses during patient treatments as
well as for drug development and approval.
______________________________________________________________

Berlin, 1st April 2014 - Alacris Theranostics has entered into a project
with SAP AG (NYSE: SAP) to use the SAP HANA(R) platform to enable Alacris'
proprietary ModCellTM system. This model is used for drug stratification
and identification of personalized drug treatments for cancer patients. The
work began through a joint project between Alacris and the SAP(R)
Innovation Center in Germany.

SAP will provide Alacris with SAP HANA and accessory software modules and
will tailor them in collaboration with Alacris to meet the needs of
ModCellTM applications. Using SAP HANA is expected to accelerate the
modelling and prediction of drug action by Alacris' ModCellTM system by a
factor of several thousand. This allows - in only a few minutes - to
identify relevant drugs and simulate their effect on individual patients
during cancer treatment, based on highly complex genome and transcriptome
data. This speed-up has the potential to be a major factor in helping
Alacris bring its ModCellTM applications into a broader clinical use.

Moreover, by using SAP HANA Alacris expects to improve the performance of
complex tasks such as simulations of single and combinatory drug action
throughout the drug development and approval processes. Saving both time
and computational resources for the simulations could potentially help
pharmaceutical companies reach decisions sooner during drug development and
approval, saving significant time and money.

Through this project, Alacris will be expanding the use of SAP HANA into
the field of personalized medicine and to the forefront of systems biology
modeling using next-generation sequencing data.

About Alacris Theranostics GmbH:

Alacris Theranostics (www.alacris.de) is a company based in Berlin
specialized in developing new approaches in personalized medicine for
cancer patient diagnosis, treatment and drug stratification. Alacris
Theranostics is applying a systems biology approach exclusively licensed as
ModCellTM to Alacris. Based on genome and transcriptome information
obtained by next generation sequencing and including kinetic pathway
information, mutation and drug databases, the systems biology approach is
providing a "Virtual Patient" model. The "Virtual Patient" model can
predict the effect of drug treatment and optimized combinatory treatment
providing means for truly personalized medicine approaches. In addition,
Alacris' "Virtual Clinical Trials" system permits the in silico analysis of
drugs, thus identifying stratified patient groups with particular genetic
and molecular profiles that could be targeted by the drug, with the goal of
more efficient drug development and approval.

# # # 

SAP, SAP HANA and all SAP logos are trademarks or registered trademarks of
SAP AG in Germany and in several other countries. All other product and
service names mentioned are the trademarks of their respective companies.

Contact:
Alacris Theranostics GmbH 
Dr Bodo Lange, CEO
Fabeckstrasse 60-62 
D-14195 Berlin 
Germany 
Phone: + 49 30 8431 22 510
Email: info@alacris.de

www.alacris.de  

MC Services AG 
Anne Hennecke, Managing Partner 
Phone +49 211 529 252 22
Email: anne.hennecke@mc-services.eu


End of Corporate News

---------------------------------------------------------------------

01.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


260789 01.04.2014